DIAGNOS announces the re-opening of its medical testing in Panama
January 28 2021 - 9:30AM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF) a leader in early detection of critical health
issues through the use of its FLAIRE platform based on Artificial
Intelligence (AI), announces today the reopening of its operations
in Panama.
“Following a long-standing presence in Panama
and in collaboration with Retina & Eye,
DIAGNOS’ distributor, we have proven the effectiveness of DIAGNOS’
AI solution. After overcoming the current lockdown of the pandemic,
CliniLab is pleased to announce it is resuming operations with
different types of projects in the public and private health
sectors in Panama, which will add value to our patients in
partnership with DIAGNOS. The implementation experience of DIAGNOS'
technology is remarkable, its turn-key solution keeps the
specialists and the patients safe and we love the principle that AI
provides. It’s a pure driven technology approach without replacing
the most important factor, the human factor, where specialists
follow up with patients using the telemedicine digital tool. We’re
adopting this new technology to positively impact the health market
in Panama, and we’re doing it with DIAGNOS”, said Mme.
Katherine Prieto, Director of Operations from
CliniLab Panama.
“This is a great opportunity for DIAGNOS to
demonstrate that our medical technology platform can easily
interconnect, not only with the ophthalmologists, but cardiologists
as well. Our CARA platform offers a real-time analysis that is
beneficial for both areas of specialties which is provided by our
Telemedicine-AI based services to screen the general population.
Early screening is key and starts at the age of 20 in order to
detect and prevent avoidable blindness in real-time. We’ve
carefully designed not only our high-tech solution, but we’ve also
put a protocol in place and a roll-out plan for CliniLab’s flagship
Telemedicine service in order to make it a sustainable project.
This will allow our retina service to remain part of every
patients’ check-up and refer them accordingly to each specialists”,
said André Larente, President of DIAGNOS.
About CLINILAB Created in 2019, the main
corporate purpose is the development, design, planning and
operations of health services, specifically in the management of
general and specialized medicine clinic by integrating clinical
laboratory services certified by the Technical Health Council as a
Level 2 laboratory: hematology, special chemistry, general
chemistry, serological test. Focused on being the main reference
among the private hospitals in the nation, we make available to our
clients the following services: general medicine, specialized
medicine, telemedicine, level 2 clinical laboratory, home or
business care, collective sampling, medical care through our mobile
unit, among others.
About DIAGNOS DIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based of its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s AI-based image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com
This press release contains forward-looking
information. We cannot guarantee that the forward-looking
information mentioned will prove to be accurate, as there may be a
significant discrepancy between actual results or future events and
those mentioned in this statement. DIAGNOS disclaims any intention
or obligation to publicly update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise. The forward-looking information contained in this
press release is expressly covered by this caution.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024